questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Isomerases
Intramolecular transferases
Phosphotransferases phosphomutases
Phosphotransferases phosphomutases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Déficience enzymatique
Phosphotransférases
Tests biochimiques
Tests enzymatiques
Phosphotransférases
Activité enzymatique
Troubles métaboliques
Fatigue
Symptômes
Tests génétiques
Mutations
Phosphotransférases
Imagerie par résonance magnétique
Phosphotransférases
Diagnostic
Symptômes
5
Déficience enzymatique
Fatigue
Symptômes
Douleurs musculaires
Troubles métaboliques
Phosphotransférases
Anomalies métaboliques
Glucides
Lipides
Âge
Développement
Symptômes
Hypoglycémie
Troubles neurologiques
Signes cliniques
Prévention
5
Prévention
Diagnostic précoce
Phosphotransférases
Conseils diététiques
Alimentation équilibrée
Nutriments
Tests de dépistage
Familles à risque
Prévention
Suivi médical
Prévention
Symptômes
Vaccinations
Prévention
Santé générale
Traitements
5
Traitement
Suppléments enzymatiques
Diète
Thérapie génique
Déficience enzymatique
Recherche
Médicaments
Gestion des symptômes
Phosphotransférases
Traitements expérimentaux
Études cliniques
Phosphotransférases
Nutrition
Gestion des symptômes
Métabolisme
Complications
5
Complications
Troubles métaboliques
Problèmes neurologiques
Complications
Gestion
Réversibilité
Qualité de vie
Complications
Activités quotidiennes
Risques
Complications à long terme
Suivi médical
Prévention
Traitement précoce
Suivi régulier
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Mutations génétiques
Environnement
Expression des gènes
Phosphotransférases
Habitudes alimentaires
Risque
Complications
Groupes à risque
Antécédents familiaux
Troubles métaboliques
Stress
Risque
Métabolisme
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Phosphotransferases phosphomutases : Questions médicales les plus fréquentes",
"headline": "Phosphotransferases phosphomutases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Phosphotransferases phosphomutases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-08",
"dateModified": "2025-03-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Phosphotransferases phosphomutases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Intramolecular transferases",
"url": "https://questionsmedicales.fr/mesh/D019751",
"about": {
"@type": "MedicalCondition",
"name": "Intramolecular transferases",
"code": {
"@type": "MedicalCode",
"code": "D019751",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.399.520"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Bisphosphoglycerate mutase",
"alternateName": "Bisphosphoglycerate Mutase",
"url": "https://questionsmedicales.fr/mesh/D001731",
"about": {
"@type": "MedicalCondition",
"name": "Bisphosphoglycerate mutase",
"code": {
"@type": "MedicalCode",
"code": "D001731",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.399.520.750.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phosphoglucomutase",
"alternateName": "Phosphoglucomutase",
"url": "https://questionsmedicales.fr/mesh/D010733",
"about": {
"@type": "MedicalCondition",
"name": "Phosphoglucomutase",
"code": {
"@type": "MedicalCode",
"code": "D010733",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.399.520.750.625"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phosphoglyceromutase",
"alternateName": "Phosphoglycerate Mutase",
"url": "https://questionsmedicales.fr/mesh/D010736",
"about": {
"@type": "MedicalCondition",
"name": "Phosphoglyceromutase",
"code": {
"@type": "MedicalCode",
"code": "D010736",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.399.520.750.700"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases phosphomutases",
"alternateName": "Phosphotransferases (Phosphomutases)",
"code": {
"@type": "MedicalCode",
"code": "D017875",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Stewart Shuman",
"url": "https://questionsmedicales.fr/author/Stewart%20Shuman",
"affiliation": {
"@type": "Organization",
"name": "Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA shumans@mskcc.org."
}
},
{
"@type": "Person",
"name": "Jean-Marc Jeckelmann",
"url": "https://questionsmedicales.fr/author/Jean-Marc%20Jeckelmann",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry and Molecular Medicine, Medical Faculty, University of Bern, Bern, Switzerland."
}
},
{
"@type": "Person",
"name": "Balraj Doray",
"url": "https://questionsmedicales.fr/author/Balraj%20Doray",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA."
}
},
{
"@type": "Person",
"name": "Benjamin C Jennings",
"url": "https://questionsmedicales.fr/author/Benjamin%20C%20Jennings",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA."
}
},
{
"@type": "Person",
"name": "Wang-Sik Lee",
"url": "https://questionsmedicales.fr/author/Wang-Sik%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Completeness of variables in Hospital-Based Cancer Registries for prostatic malignant neoplasm.",
"datePublished": "2024-07-29",
"url": "https://questionsmedicales.fr/article/39082550",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/0034-7167-2023-0467"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hepatic Small Vessel Neoplasm Mimics Prostate Cancer on 18 F-DCFPyl PET/CT.",
"datePublished": "2023-01-14",
"url": "https://questionsmedicales.fr/article/36728165",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/RLU.0000000000004554"
}
},
{
"@type": "ScholarlyArticle",
"name": "Granulomatous prostatitis: mimicking locally advanced prostate adenocarcinoma.",
"datePublished": "2023-10-17",
"url": "https://questionsmedicales.fr/article/37850783",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.23750/abm.v94i5.13751"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.",
"datePublished": "2022-12-27",
"url": "https://questionsmedicales.fr/article/36572885",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12957-022-02841-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "The influence of prostate volume on clinical parameters in prostate cancer screening.",
"datePublished": "2022-09-13",
"url": "https://questionsmedicales.fr/article/36098911",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jcla.24700"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Isomerases",
"item": "https://questionsmedicales.fr/mesh/D007535"
},
{
"@type": "ListItem",
"position": 5,
"name": "Intramolecular transferases",
"item": "https://questionsmedicales.fr/mesh/D019751"
},
{
"@type": "ListItem",
"position": 6,
"name": "Phosphotransferases phosphomutases",
"item": "https://questionsmedicales.fr/mesh/D017875"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Phosphotransferases phosphomutases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Phosphotransferases phosphomutases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Phosphotransferases phosphomutases",
"description": "Comment diagnostiquer une déficience en phosphomutases ?\nQuels tests sont utilisés pour évaluer l'activité des phosphomutases ?\nQuels symptômes peuvent indiquer un problème avec les phosphomutases ?\nLes tests génétiques sont-ils utiles pour le diagnostic ?\nQuelle imagerie peut aider à diagnostiquer des troubles liés aux phosphomutases ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Prostatic+Neoplasms#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Phosphotransferases phosphomutases",
"description": "Quels sont les symptômes d'une déficience en phosphomutases ?\nLes douleurs musculaires sont-elles liées aux phosphomutases ?\nPeut-on observer des anomalies métaboliques ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des signes cliniques spécifiques à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Prostatic+Neoplasms#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Phosphotransferases phosphomutases",
"description": "Peut-on prévenir les troubles liés aux phosphomutases ?\nY a-t-il des conseils diététiques pour prévenir les symptômes ?\nLes tests de dépistage sont-ils recommandés ?\nComment le suivi médical aide-t-il à la prévention ?\nLes vaccinations ont-elles un rôle dans la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Prostatic+Neoplasms#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Phosphotransferases phosphomutases",
"description": "Quels traitements sont disponibles pour les troubles liés aux phosphomutases ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider à gérer les symptômes ?\nY a-t-il des traitements expérimentaux en cours ?\nComment la nutrition influence-t-elle le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Prostatic+Neoplasms#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Phosphotransferases phosphomutases",
"description": "Quelles complications peuvent survenir avec une déficience en phosphomutases ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être prévenues ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Prostatic+Neoplasms#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Phosphotransferases phosphomutases",
"description": "Quels sont les facteurs de risque pour les troubles des phosphomutases ?\nL'environnement joue-t-il un rôle dans ces troubles ?\nLes habitudes alimentaires influencent-elles le risque ?\nY a-t-il des groupes à risque spécifique ?\nLe stress peut-il affecter le risque de troubles ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Prostatic+Neoplasms#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en phosphomutases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses biochimiques sont utilisés pour diagnostiquer."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des phosphomutases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'activité enzymatique in vitro mesurent la fonction des phosphomutases."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec les phosphomutases ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles métaboliques, fatigue et douleurs musculaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations spécifiques liées aux phosphomutases."
}
},
{
"@type": "Question",
"name": "Quelle imagerie peut aider à diagnostiquer des troubles liés aux phosphomutases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie par résonance magnétique (IRM) peut être utilisée pour évaluer les tissus."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en phosphomutases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, faiblesse musculaire et troubles de la croissance."
}
},
{
"@type": "Question",
"name": "Les douleurs musculaires sont-elles liées aux phosphomutases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires peuvent survenir en raison de troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Peut-on observer des anomalies métaboliques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans le métabolisme des glucides et des lipides peuvent être présentes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent se manifester différemment selon l'âge et le développement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques spécifiques à surveiller ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'hypoglycémie et des troubles neurologiques peuvent être observés."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux phosphomutases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils diététiques pour prévenir les symptômes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et riche en nutriments peut aider à prévenir certains symptômes."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de dépistage peuvent être recommandés pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical aide-t-il à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier permet de surveiller les symptômes et d'ajuster le traitement."
}
},
{
"@type": "Question",
"name": "Les vaccinations ont-elles un rôle dans la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas directement les troubles enzymatiques, mais aident à la santé générale."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles liés aux phosphomutases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments enzymatiques et des modifications diététiques."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche pour traiter certaines déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à gérer les symptômes ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments peuvent être prescrits pour gérer les symptômes associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs études cliniques explorent de nouveaux traitements pour ces troubles."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une nutrition adéquate peut améliorer la gestion des symptômes et le métabolisme."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en phosphomutases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques graves et des problèmes neurologiques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en limitant les activités quotidiennes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de complications à long terme existent, nécessitant un suivi médical."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être prévenues ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un traitement précoce et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles des phosphomutases ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines mutations génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle dans ces troubles ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux peuvent influencer l'expression des gènes liés aux phosphomutases."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une mauvaise alimentation peut exacerber les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes à risque spécifique ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes avec des antécédents familiaux de troubles métaboliques sont à risque accru."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter le risque de troubles ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut aggraver les symptômes et influencer le métabolisme."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 05/03/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA shumans@mskcc.org.
Publications dans "Phosphotransferases phosphomutases" :
3 publications dans cette catégorie
Affiliations :
Institute of Biochemistry and Molecular Medicine, Medical Faculty, University of Bern, Bern, Switzerland.
Publications dans "Phosphotransferases phosphomutases" :
3 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Publications dans "Phosphotransferases phosphomutases" :
3 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Publications dans "Phosphotransferases phosphomutases" :
3 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Publications dans "Phosphotransferases phosphomutases" :
3 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: skornfel@wustl.edu.
Publications dans "Phosphotransferases phosphomutases" :
3 publications dans cette catégorie
Affiliations :
Department of Biophysics and Chemical Biology, Seoul National University, Seoul, South Korea.
School of Biological Sciences and Institute of Microbiology, Seoul National University, Seoul, South Korea.
Publications dans "Phosphotransferases phosphomutases" :
3 publications dans cette catégorie
Affiliations :
Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Publications dans "Phosphotransferases phosphomutases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Dokkyo Medical University School of Medicine, Mibu, Tochigi 321-0293, Japan.
Publications dans "Phosphotransferases phosphomutases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Dokkyo Medical University School of Medicine, Mibu, Tochigi 321-0293, Japan h-sugi@dokkyomed.ac.jp.
Publications dans "Phosphotransferases phosphomutases" :
2 publications dans cette catégorie
Affiliations :
Department of Microbiology, Assam University, Silchar, Assam, India.
Publications dans "Phosphotransferases phosphomutases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland. Electronic address: bernhard.erni@dcb.unibe.ch.
Publications dans "Phosphotransferases phosphomutases" :
2 publications dans cette catégorie
Affiliations :
Medical Molecular Biology Laboratory, School of Medicine, Jinhua Polytechnic, Jinhua, China.
Publications dans "Phosphotransferases phosphomutases" :
2 publications dans cette catégorie
Affiliations :
The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
Key Laboratory of Medical Genetics of Zhejiang Province, Key Laboratory of Laboratory Medicine, Ministry of Education, China, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China.
Publications dans "Phosphotransferases phosphomutases" :
2 publications dans cette catégorie
Affiliations :
The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
Key Laboratory of Medical Genetics of Zhejiang Province, Key Laboratory of Laboratory Medicine, Ministry of Education, China, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China.
Publications dans "Phosphotransferases phosphomutases" :
2 publications dans cette catégorie
Affiliations :
The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
Key Laboratory of Medical Genetics of Zhejiang Province, Key Laboratory of Laboratory Medicine, Ministry of Education, China, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China.
Publications dans "Phosphotransferases phosphomutases" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Medical Genetics of Zhejiang Province, Key Laboratory of Laboratory Medicine, Ministry of Education, China, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China.
Publications dans "Phosphotransferases phosphomutases" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Medical Genetics of Zhejiang Province, Key Laboratory of Laboratory Medicine, Ministry of Education, China, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China.
Publications dans "Phosphotransferases phosphomutases" :
2 publications dans cette catégorie
Affiliations :
The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
Publications dans "Phosphotransferases phosphomutases" :
2 publications dans cette catégorie
Affiliations :
The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
Key Laboratory of Medical Genetics of Zhejiang Province, Key Laboratory of Laboratory Medicine, Ministry of Education, China, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China.
Medical Molecular Biology Laboratory, School of Medicine, Jinhua Polytechnic, Jinhua, China.
Publications dans "Phosphotransferases phosphomutases" :
to analyze the completeness of variables from Hospital-Based Cancer Registries of cases of prostate neoplasm in the Oncology Care Network of a Brazilian state between 2000 and 2020....
an ecological time series study, based on secondary data on prostate cancer Hospital-Based Cancer Registries prostate. Data incompleteness was classified as excellent (<5%), good (between 5%-10%), fai...
there were 13,519 cases of prostate cancer in the Hospital-Based Cancer Registries analyzed. The variables "family history of cancer" (p<0.001), "alcoholism" (p<0.001), "smoking" (p<0.001), "TNM stagi...
most Hospital-Based Cancer Registries variables showed excellent completeness, but important variables had high percentages of incompleteness, such as TNM and clinical staging, in addition to alcoholi...
18 F-DCFPyl is a Food and Drug Administration-approved radiotracer that targets prostate-specific membrane antigen and is used in the detection of recurrent or metastatic prostate cancer. As its use h...
We report the case of a 63-year-old male who came to the urology clinic with an increasing value of the prostate specific antigen and an asymmetrical enlargement at the digital rectal examination. The...
Biomarkers of DNA damage repair deficiency provide opportunities for personalized treatment with immunotherapy. However, there is limited research on the immune microenvironment of adeno-neuroendocrin...
A retrospective medical record review of 66 patients with prostate cancer (PCa) was performed. PCa samples from the 66 patients were analyzed using immunohistochemical staining for the detection of ch...
Twenty patients presented with adeno-NEPC, whereas 46 presented with adeno-PCa. The median age of patients at PCa diagnosis was 67.86 ± 7.05 years (68.65 ± 7.23 years, adeno-NEPC; 67.52 ± 7.02 years, ...
Our study revealed clinicopathological manifestations of adeno-NEPC and some possible predictive factors significantly associated with better outcomes in patients with adeno-NEPC. These findings might...
The purpose of the study was to evaluate the diagnostic significance of two new and a few clinical markers for prostate cancer (PCa) at various prostate volumes (PV)....
The study subjects were divided into two groups. Among them, there were 70 cases in the PV ≤30 ml group (benign prostatic hyperplasia [BPH]: 32 cases, PCa: 38 cases) and 372 cases in the PV > 30 ml gr...
In the PV ≤30 ml group, the diagnostic parameters based on prostate-specific antigen (PSA) had a decreased diagnostic significance for PCa. In the PV > 30 ml group, PSAD (AUC = 0.709), AVR (AVR = Age/...
Choosing appropriate indicators for different PVs could contribute to the early screening and diagnosis of PCa. The difference in the diagnostic value of two new indicators (A-PSAD and AVR), and PSAD ...
The optimal treatment of metastatic castration-resistant prostate cancer (mCRPC) continues to be challenging, given the multitude of life prolonging treatment options. Radionuclide therapy delivers co...
This study aims to compare the ability of the PHI versus tPSA test to predict the presence of PCa in our population....
A prospective observational study was performed. We included patients with tPSA ≥ 2.5 ng/ml, biopsy naïve or previous negative biopsy, undergoing a blood test, which includes tPSA, fPSA, and p2PSA, an...
140 men were included. Fifty-seven (40.7%) had a positive prostate biopsy result (Group A), and 83 (59.3%) had a negative biopsy result (Group B). The mean age was similar in both groups (mean ± stand...
The PHI test improves PCa detection compared to tPSA in our population....
Holmium laser enucleation of the prostate (HoLEP) is a size-independent surgical option for treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) with excellent, durable ...
Noninvasive methods for the early identify diagnosis of prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa) are current clinical challenges....
The serum metabolites of 20 healthy individuals and patients with prostatitis, BPH, or PCa were identified using untargeted liquid chromatography-mass spectrometry (LC-MS). In addition, targeted LC-MS...
Organic acid metabolites had good sensitivity and specificity in differentiating prostatitis, BPH, and PCa. Three diagnostic models identified patients with PROSTATITIS: phenyllactic acid (area under ...
We compare Prostate Health Index, Prostate Health Index density, and PSA density in predicting clinically significant prostate cancer in MRI-guided prostate biopsy....
This is a multicenter evaluation of prospectively maintained prostate biopsy databases at 10 urology centers. Men with Prostate Health Index and MRI-guided targeted and systematic prostate biopsy perf...
A total of 1,215 men were analyzed. Prostate cancer and clinically significant prostate cancer were diagnosed in 51% (617/1,215) and 35% (422/1,215) of men, respectively. Clinically significant prosta...
Prostate Health Index density outperformed Prostate Health Index or PSA density in clinically significant prostate cancer detection in men with multiparametric MRI performed, and further reduced unnec...